This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
OptiNose (OPTN) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
OptiNose (OPTN) delivered earnings and revenue surprises of 12.50% and 1.52%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Profound Medical (PROF) Surges 6.0%: Is This an Indication of Further Gains?
by Zacks Equity Research
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
OptiNose (OPTN) delivered earnings and revenue surprises of -20% and 6.67%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Durect (DRRX) delivered earnings and revenue surprises of -19.05% and 33.08%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Gain Therapeutics, Inc. (GANX) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Gain Therapeutics (GANX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will OptiNose (OPTN) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OptiNose (OPTN) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
OptiNose (OPTN) delivered earnings and revenue surprises of 10% and 0.18%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Zevra Therapeutics (ZVRA) Soars 6.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Zevra Therapeutics (ZVRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of -13.70% and 100%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
OptiNose (OPTN) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
OptiNose (OPTN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
5 Top-Ranked Stocks With Rising P/E for Solid Returns
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include Nektar Therapeutics (NKTR), Energous (WATT), DocuSign (DOCU), OptiNose (OPTN) and Canadian Solar (CSIQ).
OptiNose (OPTN) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
OptiNose (OPTN) delivered earnings and revenue surprises of 118.18% and 14.44%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Profound Medical (PROF) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Profound Medical (PROF) delivered earnings and revenue surprises of -12.90% and 21.85%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
OptiNose (OPTN) delivered earnings and revenue surprises of -6.25% and 15.01%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
OptiNose (OPTN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
OptiNose (OPTN) delivered earnings and revenue surprises of -6.25% and 3.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Silence Therapeutics PLC Sponsored ADR (SLN) Stock Jumps 9.3%: Will It Continue to Soar?
by Zacks Equity Research
Silence Therapeutics PLC Sponsored ADR (SLN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
OptiNose (OPTN) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
OptiNose (OPTN) delivered earnings and revenue surprises of -5.88% and 17.03%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Aveanna Healthcare (AVAH) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Aveanna (AVAH) delivered earnings and revenue surprises of -175% and 1.30%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
CTI BioPharma (CTIC) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
CTI BioPharma (CTIC) delivered earnings and revenue surprises of 13.33% and 0.64%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Ayala Pharmaceuticals, Inc. (AYLA) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ayala Pharmaceuticals, Inc. (AYLA) delivered earnings and revenue surprises of -20% and 88.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
OptiNose (OPTN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
OptiNose (OPTN) delivered earnings and revenue surprises of -4.55% and 7.70%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Organogenesis (ORGO) Stock Jumps 5.3%: Will It Continue to Soar?
by Zacks Equity Research
Organogenesis (ORGO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
OptiNose (OPTN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
OptiNose (OPTN) delivered earnings and revenue surprises of -29.17% and 12.48%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aurinia (AUPH) delivered earnings and revenue surprises of -3.85% and 9.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Revolution Medicines, Inc. (RVMD) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 4.88% and 24.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?